All Kinases articles
-
InterviewPhysics-based modelling offers a new way to study drug targets
Australian start-up OmnigeniQ has demonstrated what it describes as the first deterministic, physics-based computation of a human protein in its native state.
-
NewsARK1 identified as target for future malaria drugs
Scientists have identified Aurora-related kinase 1 (ARK1) as a vital protein in malaria parasite development, a breakthrough that could enable future drugs designed to block transmission.
-
NewsNew dual CDK approach tackles drug-resistant breast cancer
A new preclinical study suggests that combining next-generation CDK2 inhibitors with existing CDK4/6 therapies could overcome drug resistance in breast cancer, delivering durable tumour control across multiple subtypes.
-
NewsKinase inhibitors shown to accelerate protein breakdown
A new study has revealed that many kinase inhibitors – key drugs used in cancer and other diseases – also trigger the accelerated degradation of their target proteins, which could inform future therapies.
-
ArticleWhen chemistry corrects biology: the deuterated return of a MET inhibitor
A promising MET inhibitor failed in the clinic due to human-specific metabolism. Now its deuterated analogue, DO-2, is showing that a simple isotope swap might overcome the problem.
-
NewsGlioblastoma treatment boosted by new drug combination strategy
Researchers in China have discovered how glioblastoma adapts to low-oxygen conditions – revealing a new treatment strategy that combines an orphan drug with standard chemotherapy to overcome resistance.
-
ArticlePDX models are back – and they’re exposing what cell lines missed
As cancer drugs continue to fail in translation, researchers are turning back to patient-derived xenograft (PDX) models – this time with better science. Could they be the missing link between the lab and the clinic?
-
NewsCDK4/6 and PARP combo improves prostate cancer treatment
Researchers at VHIO have discovered a new way to overcome drug resistance in metastatic prostate cancer – by combining CDK4/6 inhibitors with follow-up therapies.
-
NewsLeukaemia cells hit hard by innovative dual-drug approach
Scientists have discovered a dual-drug therapy that dramatically increases leukaemia cell death, offering new hope for patients with acute myeloid leukaemia (AML). By combining SRC and MCL-1 inhibitors, this approach opens the door to more effective treatments.
-
NewsThe role of KDR in the survival of HTLV-1-infected T cells
KDR inhibitors could be very impactful for treatment of ATLL and HAM/TSP or prevent disease by lessening the viral load of HTLV-1.
-
NewsFinding the fundamental pathway in ALD pathogenesis
Liver-specific knockdown of TRPC3 enhanced alcohol's inhibitory effect on AMPK through a mechanism of Ca2+-dependent CaMKK2 activation.
-
NewsEnzyme substrate mutations promote tumour growth
Using a newly developed algorithm and a validation study, US researchers find that cancer hijacks a class of enzyme mutations to fuel tumorigenesis.